• Home
  • News
  • Coins2Day 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthMonsanto

Monsanto’s Roundup Is on Trial. The Charge: Causing Cancer

By
Brittany Shoot
Brittany Shoot
Down Arrow Button Icon
By
Brittany Shoot
Brittany Shoot
Down Arrow Button Icon
July 10, 2018, 6:40 PM ET
Spraying Herbicide on Dandelion
DSLR picture of spraying herbicide on Dandelion. Onfokus—Getty Images/iStockphotoOnfokus—Getty Images/iStockphoto

Does Monsanto weed killer Roundup cause cancer?

On Monday, proceedings began in San Francisco Superior Court to answer that question. The plaintiff, Dewayne “Lee” Johnson, a 46-year-old former groundskeeper at a Bay Area school district, claims Monsanto hid evidence that the active ingredient in its Roundup herbicide causes cancer. Johnson was diagnosed with non-Hodgkin lymphoma four years ago, according to the San Francisco Chronicle.

The ingredient in question is glyphosate, which California added to a list of chemicals known to cause cancer just last year. Glyphosate is also listed by the World Health Organization’s International Agency for Research on Cancer as a probable human carcinogen.

Johnson’s attorney said in opening statements that since 2000, there has been mounting evidence that glyphosate causes genetic damage. He further noted that Monsanto has worked to suppress and ignore than information.

Roundup is not the ag giant’s only concerning chemical. Another, Dicamba, is a herbicide that has been banned in Arkansas and is known to drift into other areas, compromising non-Monsanto crops.

Depending on how the Roundup trial plays out, it’s expected that Johnson’s suit, which he filed in 2016, could open the floodgates for many more similar suits against the biotech giant—up to at least 4,000 of them, according to the Chronicle.

Despite the controversy surrounding it, Roundup continues to be a lucrative product, earning Monsanto annual revenue of $4.8 billion. And regardless of the trial outcome, Monsanto will soon get the rebranding benefit of a new name, thanks to the $66 billion buyout by pharmaceutical giant Bayer.

About the Author
By Brittany Shoot
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.